BIO
Bio-Rad Laboratories, Inc. NYSE Listed Feb 27, 1980$257.16
Mkt Cap $7.0B
52w Low $211.43
34.7% of range
52w High $343.12
50d MA $276.63
200d MA $292.51
P/E (TTM)
9.2x
EV/EBITDA
19.5x
P/B
0.9x
Debt/Equity
0.2x
ROE
10.2%
P/FCF
22.1x
RSI (14)
—
ATR (14)
—
Beta
1.16
50d MA
$276.63
200d MA
$292.51
Avg Volume
303.5K
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
1000 Alfred Nobel Drive · Hercules, CA 94547 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | AMC | 1.97 | 1.89 | -4.1% | 280.12 | -6.7% | -8.4% | +0.5% | -0.3% | +0.7% | -0.7% | — |
| Feb 12, 2026 | AMC | 2.57 | 2.51 | -2.3% | 292.42 | -14.2% | -12.3% | +3.3% | +2.2% | +0.5% | -0.2% | — |
| Oct 29, 2025 | AMC | 2.30 | 2.26 | -1.7% | 319.47 | -1.1% | -4.7% | +4.9% | -2.5% | -0.2% | -0.3% | — |
| Jul 31, 2025 | AMC | 1.93 | 2.61 | +35.2% | 241.95 | +12.0% | +17.6% | -2.7% | -1.7% | -2.9% | +0.4% | — |
| May 1, 2025 | AMC | 1.73 | 2.54 | +46.8% | 240.43 | +4.0% | -1.7% | +1.6% | -3.6% | +0.4% | +3.6% | — |
| Feb 13, 2025 | AMC | 2.86 | 2.90 | +1.4% | 306.36 | -1.4% | -9.5% | +2.2% | +0.2% | +0.7% | -1.9% | — |
| Oct 30, 2024 | AMC | 1.28 | 2.01 | +57.0% | 330.58 | +5.4% | +8.4% | +2.9% | +0.1% | +1.5% | -0.4% | — |
| Aug 1, 2024 | AMC | 2.12 | 3.11 | +46.7% | 341.25 | -1.4% | -1.6% | -2.2% | -0.5% | -2.5% | +3.0% | — |
| May 7, 2024 | AMC | 2.15 | 2.29 | +6.5% | 279.91 | -2.6% | -4.2% | +3.4% | +1.7% | +1.2% | +3.0% | — |
| Feb 15, 2024 | AMC | 2.93 | 3.10 | +5.8% | 328.73 | +6.5% | +3.6% | +1.0% | -1.5% | -0.1% | -0.1% | — |
| Oct 26, 2023 | AMC | 2.87 | 2.33 | -18.8% | 291.53 | -5.9% | -7.2% | -0.5% | +2.2% | +0.8% | +1.3% | — |
| Aug 3, 2023 | AMC | 2.55 | 3.00 | +17.6% | 401.80 | +1.7% | -0.4% | +0.4% | +0.3% | -1.5% | +0.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $280.12 | $261.47 | -6.7% | -8.4% | +0.5% | -0.3% | +0.7% | -0.7% |
| Apr 7 | Citigroup | Downgrade | Buy → Neutral | — | $278.85 | $272.21 | -2.4% | -0.3% | +1.1% | -1.3% | +0.6% | +3.2% |
| Oct 30 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $319.47 | $316.00 | -1.1% | -4.7% | +4.9% | -2.5% | -0.2% | -0.3% |
| Oct 30 | Citigroup | Maintains | Buy → Buy | — | $319.47 | $316.00 | -1.1% | -4.7% | +4.9% | -2.5% | -0.2% | -0.3% |
| Aug 1 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $241.95 | $270.93 | +12.0% | +17.6% | -2.7% | -1.7% | -2.9% | +0.4% |
| Aug 1 | RBC Capital | Maintains | Outperform → Outperform | — | $241.95 | $270.93 | +12.0% | +17.6% | -2.7% | -1.7% | -2.9% | +0.4% |
| Jun 9 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $219.42 | $222.81 | +1.5% | +2.8% | +2.2% | -0.1% | +1.0% | -2.4% |
| May 2 | Citigroup | Maintains | Buy → Buy | — | $240.43 | $250.00 | +4.0% | -1.7% | +1.6% | -3.6% | +0.4% | +3.6% |
| May 2 | UBS | Maintains | Buy → Buy | — | $240.43 | $250.00 | +4.0% | -1.7% | +1.6% | -3.6% | +0.4% | +3.6% |
| May 2 | RBC Capital | Maintains | Outperform → Outperform | — | $240.43 | $250.00 | +4.0% | -1.7% | +1.6% | -3.6% | +0.4% | +3.6% |
| Apr 17 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $245.21 | $243.06 | -0.9% | -2.9% | -0.5% | +3.4% | +1.6% | +0.4% |
| Feb 12 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $314.73 | $310.70 | -1.3% | -0.8% | -1.9% | -9.5% | +2.2% | +0.2% |
| Jan 14 | RBC Capital | Maintains | Outperform → Outperform | — | $351.70 | $351.70 | +0.0% | -2.7% | -0.1% | +0.8% | -0.6% | +3.3% |
| Dec 9 | RBC Capital | Maintains | Outperform → Outperform | — | $325.50 | $324.83 | -0.2% | +6.2% | -1.7% | +0.5% | -0.4% | -1.1% |
| Oct 31 | RBC Capital | Maintains | Outperform → Outperform | — | $330.58 | $348.47 | +5.4% | +8.4% | +2.9% | +0.1% | +1.5% | -0.4% |
| Oct 31 | Citigroup | Maintains | Buy → Buy | — | $330.58 | $348.47 | +5.4% | +8.4% | +2.9% | +0.1% | +1.5% | -0.4% |
| Oct 1 | Citigroup | Upgrade | Neutral → Buy | — | $334.58 | $338.55 | +1.2% | +0.9% | +1.5% | -1.6% | +2.0% | -0.8% |
| Aug 16 | RBC Capital | Maintains | Outperform → Outperform | — | $325.62 | $325.59 | -0.0% | -0.0% | +0.2% | -2.3% | -0.8% | -2.0% |
| Aug 2 | RBC Capital | Maintains | Outperform → Outperform | — | $341.25 | $336.54 | -1.4% | -1.6% | -2.2% | -0.5% | -2.5% | +3.0% |
| Aug 2 | Citigroup | Maintains | Neutral → Neutral | — | $341.25 | $336.54 | -1.4% | -1.6% | -2.2% | -0.5% | -2.5% | +3.0% |
| May 8 | UBS | Maintains | Buy → Buy | — | $279.91 | $272.52 | -2.6% | -4.2% | +3.4% | +1.7% | +1.2% | +3.0% |
| Apr 3 | Citigroup | Downgrade | Buy → Neutral | — | $328.72 | $322.13 | -2.0% | -0.2% | -1.6% | +0.5% | +0.5% | +4.0% |
| Feb 16 | UBS | Maintains | Buy → Buy | — | $328.73 | $350.00 | +6.5% | +3.6% | +1.0% | -1.5% | -0.1% | -0.1% |
| Feb 16 | RBC Capital | Maintains | Outperform → Outperform | — | $328.73 | $350.00 | +6.5% | +3.6% | +1.0% | -1.5% | -0.1% | -0.1% |
| Aug 7 | Wells Fargo | Maintains | Overweight → Overweight | — | $400.00 | $398.54 | -0.4% | +0.4% | +0.3% | -1.5% | +0.3% | -0.2% |
| Aug 4 | Credit Suisse | Maintains | Outperform → Outperform | — | $401.80 | $408.79 | +1.7% | -0.4% | +0.4% | +0.3% | -1.5% | +0.3% |
| Aug 4 | RBC Capital | Maintains | Outperform → Outperform | — | $401.80 | $408.79 | +1.7% | -0.4% | +0.4% | +0.3% | -1.5% | +0.3% |
| May 8 | RBC Capital | Maintains | Outperform → Outperform | — | $385.24 | $384.69 | -0.1% | -1.8% | -3.0% | -0.3% | -0.4% | +2.2% |
| May 8 | Citigroup | Maintains | Buy → Buy | — | $385.24 | $384.69 | -0.1% | -1.8% | -3.0% | -0.3% | -0.4% | +2.2% |
| May 5 | Credit Suisse | Maintains | Outperform → Outperform | — | $462.61 | $400.00 | -13.5% | -16.7% | -1.8% | -3.0% | -0.3% | -0.4% |
| Feb 17 | Credit Suisse | Maintains | Outperform → Outperform | — | $455.91 | $455.00 | -0.2% | +6.0% | -3.1% | +1.7% | +2.3% | -1.4% |
| Feb 17 | RBC Capital | Maintains | Outperform → Outperform | — | $455.91 | $455.00 | -0.2% | +6.0% | -3.1% | +1.7% | +2.3% | -1.4% |
| Dec 7 | RBC Capital | Maintains | Outperform → Outperform | — | $399.59 | $401.97 | +0.6% | +1.1% | +4.0% | -1.0% | +0.5% | +4.0% |
| Oct 28 | Credit Suisse | Maintains | Outperform → Outperform | — | $385.02 | $365.70 | -5.0% | -8.0% | -0.7% | +1.9% | -0.7% | +2.6% |
| Aug 25 | Credit Suisse | Maintains | Outperform → Outperform | — | $499.09 | $505.55 | +1.3% | +3.1% | -3.8% | -1.4% | -1.0% | +0.3% |
| Jul 8 | Citigroup | Maintains | Buy → Buy | — | $512.54 | $506.13 | -1.3% | +0.9% | +0.9% | -4.1% | -0.2% | -2.2% |
| Jul 30 | Wells Fargo | Maintains | Overweight → Overweight | — | $707.13 | $713.11 | +0.8% | +4.6% | -0.4% | +1.3% | +2.2% | +0.2% |
| Feb 12 | Citigroup | Maintains | Buy → Buy | — | $643.81 | $650.00 | +1.0% | +2.9% | -1.9% | +0.9% | -0.6% | -2.2% |
| Feb 5 | Jefferies | Maintains | Buy → Buy | — | $605.01 | $608.62 | +0.6% | +1.9% | +2.0% | +1.2% | -0.7% | +1.9% |
| Jul 31 | Citigroup | Maintains | Buy → Buy | — | $535.60 | $524.93 | -2.0% | -2.0% | +1.2% | -0.8% | +0.1% | -0.4% |
| May 21 | Wells Fargo | Maintains | Overweight → Overweight | — | $472.94 | $474.90 | +0.4% | -1.3% | +1.2% | +1.8% | -2.2% | +1.4% |
| May 7 | Citigroup | Maintains | Buy → Buy | — | $449.99 | $464.46 | +3.2% | +2.3% | -0.9% | +3.1% | -1.9% | -1.4% |
| Apr 20 | Citigroup | Maintains | Buy → Buy | — | $427.21 | $426.12 | -0.3% | -0.5% | -1.7% | +0.9% | +0.4% | +2.3% |
| Mar 30 | Wells Fargo | Maintains | Overweight → Overweight | — | $322.41 | $326.18 | +1.2% | +8.3% | +0.4% | -4.5% | +7.7% | +1.4% |
| Mar 26 | Barclays | Maintains | Overweight → Overweight | — | $333.00 | $337.37 | +1.3% | +2.5% | -5.5% | +8.3% | +0.4% | -4.5% |
| Mar 20 | Citigroup | Maintains | Buy → Buy | — | $346.80 | $347.35 | +0.2% | -5.1% | -0.8% | +5.2% | -3.0% | +2.5% |
| Feb 14 | Wells Fargo | Maintains | Overweight → Overweight | — | $379.34 | $380.70 | +0.4% | +6.4% | +0.9% | +0.4% | +0.0% | -2.1% |
| Jan 8 | Wells Fargo | Maintains | Overweight → Overweight | — | $380.54 | $384.25 | +1.0% | +0.3% | +1.8% | -1.3% | +0.2% | +0.0% |
| Jan 7 | Citigroup | Maintains | Buy → Buy | — | $372.03 | $374.94 | +0.8% | +2.3% | +0.3% | +1.8% | -1.3% | +0.2% |
| Aug 20 | Goldman Sachs | Upgrade | Buy → Conviction Buy | — | $330.95 | $336.90 | +1.8% | +2.9% | +1.1% | -0.7% | -2.7% | +0.8% |
No insider trades available.
8-K · 5.02
!!! Very High
Bio-Rad Laboratories, Inc.Class A -- 8-K 5.02: Executive Change
Bio-Rad's departure of a key executive creates leadership uncertainty that could impact operational continuity and investor confidence, warranting caution until a qualified successor is named.
Apr 24
8-K · 7.01
! Medium
Bio-Rad Laboratories, Inc.Class A -- 8-K 7.01: Regulation FD Disclosure
Bio-Rad Laboratories disclosed updated financial information regarding its Sartorius AG investment following Sartorius's 2025 earnings release, providing investors transparency on this significant equity holding's performance.
Feb 19
8-K · 7.01
! Medium
Bio-Rad Laboratories, Inc.Class A -- 8-K 7.01: Regulation FD Disclosure
Bio-Rad Laboratories disclosed supplemental earnings presentation materials under Regulation FD, providing investors with additional financial and operational details beyond standard earnings reports.
Feb 12
Data updated apr 24, 2026 9:39pm
· Source: massive.com